» Articles » PMID: 24432870

Back Pocket Flexibility Provides Group II P21-activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors

Abstract

Structure-based methods were used to design a potent and highly selective group II p21-activated kinase (PAK) inhibitor with a novel binding mode, compound 17. Hydrophobic interactions within a lipophilic pocket past the methionine gatekeeper of group II PAKs approached by these type I 1/2 binders were found to be important for improving potency. A structure-based hypothesis and strategy for achieving selectivity over group I PAKs, and the broad kinome, based on unique flexibility of this lipophilic pocket, is presented. A concentration-dependent decrease in tumor cell migration and invasion in two triple-negative breast cancer cell lines was observed with compound 17.

Citing Articles

Design, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-]pyridine derivatives as p21-activated kinase 4 inhibitors for treatment of pancreatic cancer.

Li Y, Fang Y, Chen X, Tong L, Feng F, Zhou Q Acta Pharm Sin B. 2025; 15(1):438-466.

PMID: 40041917 PMC: 11873650. DOI: 10.1016/j.apsb.2024.10.002.


Identification of Potential Selective PAK4 Inhibitors Through Shape and Protein Conformation Ensemble Screening and Electrostatic-Surface-Matching Optimization.

Zhang X, Zhang M, Li Y, Deng P Curr Issues Mol Biol. 2025; 47(1.

PMID: 39852144 PMC: 11764389. DOI: 10.3390/cimb47010029.


Inhibition of NAMPT by PAK4 Inhibitors.

Wang Y, Minden A Int J Mol Sci. 2024; 25(18).

PMID: 39337621 PMC: 11431865. DOI: 10.3390/ijms251810138.


Novel quinoxaline-3-propanamides as VGFR-2 inhibitors and apoptosis inducers.

Ismail M, Shawer T, Ibrahim R, Abusaif M, Kamal M, Allam R RSC Adv. 2023; 13(45):31908-31924.

PMID: 37915441 PMC: 10616755. DOI: 10.1039/d3ra05066a.


Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents.

Li Y, Lu Q, Xie C, Yu Y, Zhang A Front Pharmacol. 2022; 13:956220.

PMID: 36105226 PMC: 9465411. DOI: 10.3389/fphar.2022.956220.